358 related articles for article (PubMed ID: 33609783)
1. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.
Latil M; Camelo S; Veillet S; Lafont R; Dilda PJ
Drug Discov Today; 2021 May; 26(5):1311-1318. PubMed ID: 33609783
[TBL] [Abstract][Full Text] [Related]
2. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
4. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
7. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
Ferrara F; Vitiello A
Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
[TBL] [Abstract][Full Text] [Related]
8. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19.
Shete A
Int J Infect Dis; 2020 Jul; 96():348-351. PubMed ID: 32389847
[TBL] [Abstract][Full Text] [Related]
9. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptors: Impact for COVID-19 severity.
Aksoy H; Karadag AS; Wollina U
Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
[TBL] [Abstract][Full Text] [Related]
11. The renin-angiotensin system in COVID-19: Why ACE2 targeting by coronaviruses produces higher mortality in elderly hypertensive patients?
Kurbel S
Bioessays; 2021 Mar; 43(3):e2000112. PubMed ID: 33336824
[TBL] [Abstract][Full Text] [Related]
12. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
Albashir AAD
South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362
[TBL] [Abstract][Full Text] [Related]
13. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
14. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
15. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications.
Ning L; Rong J; Zhang Z; Xu Y
Pharmacol Res; 2021 May; 167():105409. PubMed ID: 33465472
[TBL] [Abstract][Full Text] [Related]
17. ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases.
Bank S; De SK; Bankura B; Maiti S; Das M; A Khan G
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33442728
[TBL] [Abstract][Full Text] [Related]
18. ACE2 in the renin-angiotensin system.
Verano-Braga T; Martins ALV; Motta-Santos D; Campagnole-Santos MJ; Santos RAS
Clin Sci (Lond); 2020 Dec; 134(23):3063-3078. PubMed ID: 33264412
[TBL] [Abstract][Full Text] [Related]
19. Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system.
Xu C; Chen Y; Yu J
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):1-11. PubMed ID: 35130610
[TBL] [Abstract][Full Text] [Related]
20. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
Sriram K; Loomba R; Insel PA
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29274-29282. PubMed ID: 33203679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
